Adalimumab Induced Acute Exacerbation of Rheumatoid Arthritis Related Interstitial Lung Disease.
10.4235/jkgs.2013.17.3.134
- Author:
Woo Kyung PARK
1
;
Youn Sun LEE
;
Sam WON
;
Hye Reen KIM
;
Jeong Hun LEE
;
Kwang Bok LEE
;
Jong Hyun KIM
Author Information
1. Department of Internal Medicine, Daejeon Sun Hospital, Daejeon, Korea. cnu4169@hanmail.net
- Publication Type:Case Report
- Keywords:
Adalimumab;
Rheumatoid arthritis;
Interstitial lung disease
- MeSH:
Aged;
Antibodies, Monoclonal, Humanized;
Arthritis;
Arthritis, Rheumatoid;
Female;
Humans;
Hydroxychloroquine;
Lung Diseases, Interstitial;
Methylprednisolone;
Sulfasalazine;
Tumor Necrosis Factor-alpha;
Adalimumab
- From:Journal of the Korean Geriatrics Society
2013;17(3):134-137
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 69-year-old woman with 6 years history of seropositive rheumatoid arthritis (RA) and asymptomatic interstitial lung disease (ILD) began taking adalimumab for ongoing arthritis despite intakes of sulfasalazine and hydroxychloroquine for treatment. ILD progressed noticeably after 10 weeks of starting adalimumab. We discontinued adalimumab and added methylprednisolone 40 mg, and the patient's clinical findings gradually improved. The beneficial and adverse effects of tumor necrosis factor-alpha (TNF-alpha) inhibitors on RA associated ILD are unclear but this case reports adalimumab could abruptly exacerbate known ILD. We emphasize cautions on the use of adalimumab, one of the TNF-alpha inhibitors, in elderly RA patients with preexisting ILD.
